Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Nicholas

Showing results (81-90 of 165) with videos related to

Pageof 17
Sort By:
Plos One|October 16, 2020
A realist review of advance care planning for people with multiple sclerosis and their familiesLaura Cottrell, Guillaume Economos, Catherine Evans, et al.
Plos One|May 26, 2022
"I wanna live and not think about the future" what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative studyJonathan Koffman, Clarissa Penfold, Laura Cottrell, et al.
Neurobiology of Disease|February 11, 2014
Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot studyPaolo Giannetti, Marios Politis, Paul Su, et al.
Immunology|August 3, 2017
Programmed death 1 is highly expressed on CD8<sup>+</sup> CD57<sup>+</sup> T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virusMaria T Cencioni, Roberta Magliozzi, Richard Nicholas, et al.
Neurology|March 13, 2015
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosisMiriam Mattoscio, Richard Nicholas, Maria P Sormani, et al.
Applied Health Economics and Health Policy|May 18, 2022
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis PatientsKristyna Lacinova, Praveen Thokala, Richard Nicholas, et al.
The Lancet. Neurology|June 11, 2017
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trialDennis Chan, Sophie Binks, Jennifer M Nicholas, et al.
Nature Reviews. Neurology|November 27, 2025
Towards primary prevention of multiple sclerosisRuth Dobson, Karim L Kreft, Benjamin M Jacobs, et al.
Journal of Neuroinflammation|December 8, 2019
Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosisRoberta Magliozzi, Owain William Howell, Pascal Durrenberger, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
A pragmatic approach to dealing with fingolimod-related lymphopaenia in EuropeGavin Giovannoni, Brigit de Jong, Tobias Derfuss, et al.
Pageof 17

Showing results (81-90 of 165) with videos related to

Sort By:
Pageof 17
Plos One|October 16, 2020
A realist review of advance care planning for people with multiple sclerosis and their familiesLaura Cottrell, Guillaume Economos, Catherine Evans, et al.
Plos One|May 26, 2022
"I wanna live and not think about the future" what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative studyJonathan Koffman, Clarissa Penfold, Laura Cottrell, et al.
Neurobiology of Disease|February 11, 2014
Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot studyPaolo Giannetti, Marios Politis, Paul Su, et al.
Immunology|August 3, 2017
Programmed death 1 is highly expressed on CD8<sup>+</sup> CD57<sup>+</sup> T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virusMaria T Cencioni, Roberta Magliozzi, Richard Nicholas, et al.
Neurology|March 13, 2015
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosisMiriam Mattoscio, Richard Nicholas, Maria P Sormani, et al.
Applied Health Economics and Health Policy|May 18, 2022
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis PatientsKristyna Lacinova, Praveen Thokala, Richard Nicholas, et al.
The Lancet. Neurology|June 11, 2017
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trialDennis Chan, Sophie Binks, Jennifer M Nicholas, et al.
Nature Reviews. Neurology|November 27, 2025
Towards primary prevention of multiple sclerosisRuth Dobson, Karim L Kreft, Benjamin M Jacobs, et al.
Journal of Neuroinflammation|December 8, 2019
Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosisRoberta Magliozzi, Owain William Howell, Pascal Durrenberger, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
A pragmatic approach to dealing with fingolimod-related lymphopaenia in EuropeGavin Giovannoni, Brigit de Jong, Tobias Derfuss, et al.
Pageof 17